Capital Fund Management (CFM)’s Haemonetics HAE Stock Holding History

Capital Fund Management (CFM)’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,338	Closed	-$995K	–	2550
2025 Q2	$995K	Buy	+13,338	New	+$883K	﹤0.01%	2002
2022 Q4	–	Sell	-16,728	Closed	-$1.24M	–	1479
2022 Q3	$1.24M	Sell	16,728 -966	-5%	-$69.4K	0.01%	1020
2022 Q2	$1.15M	Buy	+17,694	New	+$1.05M	0.01%	1025
2019 Q4	–	Sell	-15,493	Closed	-$1.95M	–	1900
2019 Q3	$1.95M	Sell	15,493 -17,404	-53%	-$2.21M	0.02%	800
2019 Q2	$3.96M	Sell	32,897 -21,004	-39%	-$2.07M	0.04%	590
2019 Q1	$4.71M	Sell	53,901 -1,169	-2%	-$106K	0.04%	519
2018 Q4	$5.51M	Sell	55,070 -99,685	-64%	-$10.5M	0.05%	476
2018 Q3	$17.7M	Buy	154,755 +53,896	+53%	+$5.58M	0.1%	310
2018 Q2	$9.04M	Buy	+100,859	New	+$8.52M	0.05%	514

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Fund Management (CFM)'s HAE Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Haemonetics (HAE) in Q3 2025, closing a stake of 13,338 shares — an estimated $995K sold.

Capital Fund Management (CFM) first reported a position in HAE in Q2 2018 and held it in 9 quarters. The position peaked at $17.7M in Q3 2018. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.

Capital Fund Management (CFM) reported no remaining Haemonetics position as of Q3 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 13,338 Haemonetics shares in Q3 2025, an estimated $995K.
Capital Fund Management (CFM) first reported a position in Haemonetics in Q2 2018 and held it in 9 quarters.
Capital Fund Management (CFM)'s Haemonetics position peaked at $17.7M in Q3 2018.
301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.